-
Duchenne Patients Again Being Treated in HOPE-2 Potential Cell Therapy Trial, Capricor Announces
Dosing of Duchenne muscular dystrophy patients has resumed in the Phase 2 trial of CAP-1002 cell therapy; all will be checked for potential allergies. Read more about the trial here.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.